Biespecifics Talks
Where it charts
Today’s combined position on our country charts.
Ranking history
About the show
Latest episodes
-
1x06: Bispecific Antibodies – Overview of Safety Profile – Infections
April 9, 2026 · 18 minThis chapter focuses on infections, one of the most important safety considerations in patients receiving bispecific antibody therapy for relapsed and refractory multiple myeloma. It explores why these infections occur, how their incidence…
-
1x05: Bispecific Antibodies – : Overview of Safety Profile – On-Target Off-Tumor Toxicities
April 9, 2026 · 36 minThis chapter focuses on on-target off-tumor toxicities associated with bispecific antibody therapy in relapsed and refractory multiple myeloma. It explores why these side effects occur, how they vary across different therapeutic targets…
-
1x04 Bispecific Antibodies – Overview of Safety Profile – Neurological Complications
April 9, 2026 · 19 minThis chapter focuses on the neurological complications associated with bispecific antibody therapy in relapsed and refractory multiple myeloma, with particular attention to ICANS. It explains why this toxicity occurs, how frequently and…
-
1x03 Biespecifics talks: Overview of Safety Profile – Cytokine Release Syndrome
April 9, 2026 · 26 minThis chapter focuses on cytokine release syndrome, one of the best-known side effects of bispecific antibody therapy in relapsed and refractory multiple myeloma. It explains why CRS occurs, how often and how severely it appears across…
-
1x02 Biespecifics talks: Overview of Treatment Efficacy of Different Constructs
April 9, 2026 · 24 minThis chapter focuses on the efficacy of bispecific antibodies in relapsed and refractory multiple myeloma, examining how the currently approved therapies perform across different patient groups and treatment settings. It explores when…
-
1x01: Bispecific Antibodies – A New Treatment Modality for the management of RRMM
April 9, 2026 · 17 minThis first chapter introduces bispecific antibodies as a new treatment approach for relapsed and refractory multiple myeloma. It explains how these therapies work, why targets such as BCMA and GPRC5D are important, how the currently…